The Cooper Companies (COO) Stock: Falls Despite Strong Q1 Revenue and 20% EPS Growth

TLDR

• COO Q1 revenue rises 6.2% to $1.024B, yet shares drop 2.17%.
• Non-GAAP EPS jumps 20% to $1.10; full-year guidance raised.
• CooperVision grows 7.6%, driven by MyDay and MiSight lenses.
• Asia-Pacific sales decline 4%, led by legacy hydrogel weakness.
• CooperSurgical revenue rises 3.3%, free cash flow hits $159M.

The Cooper Companies, Inc. (COO) shares declined despite reporting solid fiscal first-quarter performance and stronger earnings growth. The stock closed at $80.20, falling 2.17%, and later slid further to $75.23 during pre-market trading. The decline followed a results release showing higher revenue, stronger margins, and improved earnings guidance.

The Cooper Companies, Inc., COO

Strong revenue growth and margin expansion support quarterly performance

The company generated $1.024 billion in consolidated revenue during the first fiscal quarter. That figure marked a 6.2% increase compared with the same period last year. Organic revenue also grew 2.9%, reflecting steady demand across key product segments.

Operating performance improved as cost controls and restructuring benefits supported profitability. Non-GAAP gross margin reached 68.1%, while operating margin expanded to 26.9%. Consequently, operating expenses declined as a share of revenue compared with the prior year.

Non-GAAP earnings per share increased 20% to $1.10 during the quarter. The company also maintained roughly 197 million average shares outstanding. Management raised full-year non-GAAP EPS guidance to a range between $4.58 and $4.66.

CooperVision growth driven by premium lens adoption

CooperVision delivered $695 million in quarterly revenue and recorded 7.6% year-over-year growth. Organic revenue in the segment increased 3.3%, reflecting stable global contact lens demand. Product innovation and geographic expansion supported the segment’s performance.

The rollout of MyDay premium lenses contributed to stronger product adoption across several international markets. In addition, MiSight lenses continued expanding within the myopia management segment. MiSight revenue rose 23% year over year and reached $28 million.

However, the Asia-Pacific region posted a 4% revenue decline during the quarter. Weakness in legacy hydrogel products in Japan drove the regional drop. Management expects softness to continue in the second quarter before returning to growth during the third quarter.

CooperSurgical shows early stabilization and strong cash generation

CooperSurgical reported quarterly revenue of $329 million and achieved 3.3% year-over-year growth. Organic growth reached 2.2%, indicating steady improvement across the medical device portfolio. Fertility products showed early signs of demand stabilization.

Fertility revenue totaled $127 million during the quarter and rose 3% on an organic basis. The segment benefited from improving procedure activity and consistent product demand. This performance supported gradual recovery within the reproductive health market.

The company generated $159 million in free cash flow during the quarter. It repurchased 1.1 million shares for $92 million and extended $950 million of term debt to February 2031. Net debt declined to approximately $2.4 billion as balance sheet conditions improved.

Management continues focusing on market share expansion, operational efficiency, and disciplined capital allocation. These efforts support long-term growth across both operating divisions. Despite these developments, the stock moved lower following the earnings release and extended losses in early trading.

The post The Cooper Companies (COO) Stock: Falls Despite Strong Q1 Revenue and 20% EPS Growth appeared first on CoinCentral.